Examining Blood and Tissue Samples to Identify Diagnostic Markers in Patients With Metastatic Cancer Undergoing Tumor Removal

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

50 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-06-29

Study Completion Date

2028-04-07

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study characterizes deoxyribonucleic acid (DNA) and proteomic (protein) changes in both biopsies and tumors removed during surgery of patients who have been diagnosed with aggressive/metastatic (that has spread to other places in the body) cancer in order to identify possible diagnostic markers and potential drugs for treating aggressive tumor types. Proteomic analyses include looking at the proteome, or all the proteins expressed, or made by DNA at a specific moment in time. Studying samples of blood, buccal (cheek), and tissue in the laboratory from patients undergoing surgical resection or biopsy may help doctors learn more about the changes that occur in the proteome, DNA alterations, and identify molecular biomarkers for which therapeutic drugs may exist. Studying the DNA in tumor tissue and in blood may also help researchers see if the tumor has important differences.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Pilot Study Utilizing Proteomic and Genomic Profiling for Patients With Metastatic Breast Cancer

NCT01919749

Metastatic Breast Cancer

COMPLETED NA

Studying DNA in Tumor Tissue Samples From Patients With Localized or Metastatic Osteosarcoma

NCT01062438

Sarcoma

COMPLETED

Cell-Free DNA and RNA in Blood fromMetastatic Prostate Cancer Patients

NCT02853097

Hormone-Resistant Prostate Cancer Metastatic Prostate Carcinoma Prostate Adenocarcinoma

TERMINATED

Measuring Cell Free DNA During the Course of Treatment for Esophageal Cancer as a Marker of Response and Recurrence

NCT03108885

Esophageal Neoplasm Esophageal Neoplasms Malignancy Unspecified Esophageal Neoplasms Malignant +5 more

TERMINATED

Genomic Profiling in Recommending Treatment for Patients With Metastatic Solid Tumors

NCT02215928

Unspecified Adult Solid Tumor, Protocol Specific

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

PRIMARY OBJECTIVES:

I. To understand the pathogenesis, molecular mechanisms, and disease processes of malignancies.

II. To examine the utility of integrated genomics for discovery of targets or pathways involved in tumor/malignancy progression of patients with malignancies.

III. To observe for any evidence of anti-tumor activity from treatment if selected based on integrated genomics.

IV. To create and offer opportunities for targeted individualized therapy based on the outcome of integrated genomics and micro-cancer modeling.

V. To determine the outcome of patients with malignancies who received targeted individualized therapy.

OUTLINE: This is an ancillary-correlative study.

Patients undergo collection of blood and buccal samples before or after standard of care (SOC) biopsy or tumor resection. Patients undergo collection of tumor tissue at time of SOC biopsy or tumor resection. Patients' medical records are also reviewed. Patients' archived tissue or blood samples may also be collected.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hematopoietic and Lymphoid System Neoplasm Metastatic Malignant Solid Neoplasm

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

OTHER

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ancillary-Correlative (biospecimen collection)

Patients undergo collection of blood and buccal samples before or after SOC biopsy or tumor resection. Patients undergo collection of tumor tissue at time of SOC biopsy or tumor resection. Patients' medical records are also reviewed. Patients' archived tissue or blood samples may also be collected.

Biopsy Specimen

Intervention Type PROCEDURE

Undergo collection of tissue samples

Biospecimen Collection

Intervention Type PROCEDURE

Undergo collection of blood and buccal swab samples

Biospecimen Collection

Intervention Type PROCEDURE

Undergo collection of archived tissue and blood samples

Medical Chart Review

Intervention Type OTHER

Review of medical record

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Biopsy Specimen

Undergo collection of tissue samples

Intervention Type PROCEDURE

Biospecimen Collection

Undergo collection of blood and buccal swab samples

Intervention Type PROCEDURE

Biospecimen Collection

Undergo collection of archived tissue and blood samples

Intervention Type PROCEDURE

Medical Chart Review

Review of medical record

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Biopsy Sample Biological Sample Collection Biospecimen Collected Specimen Collection Biological Sample Collection Biospecimen Collected Specimen Collection Chart Review

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients (or the legally authorized representative/guardian signing on behalf of the participant) must understand and provide written informed consent prior to initiation of any study-specific procedures
* \>= 18 years of age
* Patients must have a diagnosis of confirmed malignancy
* Patient is a good medical candidate for a standard of care biopsy or surgical procedure to obtain tissue or has archival tissue available for analysis

Exclusion Criteria

* Uncontrolled concurrent illness including psychiatric illness, or situations that would limit compliance with the study requirements or the ability to willingly give written informed consent
* Inaccessible tumor for biopsy or patient does not have tumor tissue available for research use
* Biopsy must not be considered to be more than minimal risk to the patient. Contraindications to percutaneous biopsy:

* Significant coagulopathy that cannot be adequately corrected
* Severely compromised cardiopulmonary function or hemodynamic instability
* Lack of a safe pathway to the lesion
* Inability of the patient to cooperate with, or to be positioned for, the procedure

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No